Issue link: https://www.e-digitaleditions.com/i/1546950
The surge in antimicrobial resistance (AMR) is one of the top threats to global public health. Annual deaths due to AMR bacteria numbered 5 million in 2019, with more than 1.5 million deaths related to lower respiratory tract infections. It has been estimated there will be more than 10 million deaths annually by 2050 if antibiotic resistance remains unchecked. 24 OctOber 2026 Inhalation Promises and challenges in inhaled phage therapy for pulmonary infections Advancing phage delivery to the lungs Shruti S. Sawant, MS Purdue University Introduction e surge in antimicrobial resistance (AMR) is one of the top threats to global public health. Annual deaths due to AMR bacteria numbered 5 million in 2019, with more than 1.5 million deaths related to lower respiratory tract infections [1]. It has been estimated there will be more than 10 million deaths annually by 2050 if antibiotic resistance remains unchecked [2]. e World Health Organization (WHO) has identi- fied highly antibiotic-resistant bacterial species, col- lectively called ESKAPE pathogens, which include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomo- nas aeruginosa. ese pathogens (except E. faecium) can cause respiratory infections such as ventilator- associated pneumonia and hospital-acquired pneu- monia and infections in patients with cystic fibrosis [3]. Antibiotic-resistant bacteria continue to evolve resistance mechanisms to escape the action of exist- ing antibiotics. As therapeutic options have become limited, the production of new antibiotics has mark- edly dwindled [4]. e relatively dry antibiotic pipeline and escalation of AMR have spurred a need for alternative strategies against multidrug-resistant bacteria. Consequently, bacteriophages (phages) have gained renewed inter- est as alternatives to conventional antibiotics. Phages are naturally occurring viruses that can specifically infect and kill bacteria. Phages were discovered in the pre-antibiotic era but failed to gain traction com- pared to antibiotics due to limited understanding of phage biology [5]. Currently, phage therapy is in clinical trials and as yet there are no approved com- mercial products in the United States. e US Food and Drug Administration (FDA) provided phage therapy an emergency authorization, under compas- Respiratory Infection Bacteria Phage Formulation and Administration Sponsor Clinical Trial Identifier Non-cystic fibrosis bronchiectasis P. aeruginosa AP-PA02 (phage cocktail) by nebulization Armata Pharmaceuticals NCT05616221 (Tailwind) Chronic pulmonary infection P. aeruginosa Phage cocktail AP-PA02 administered via nebulization Armata Pharmaceuticals NCT04596319 (SWARM-Pa) Pulmonary infection P. aeruginosa (PsA) BX004 given by nebulization BiomX, Inc. NCT06998043 Cystic fibrosis P. aeruginosa (PsA) YPT-01 phage cocktail ≥ 10 8 PFU/mL in PBS and 10 mM magnesium sulfate (MgSO 4 ) using SideStream nebulizer Yale University NCT04684641 (CYPHY) Cystic fibrosis P. aeruginosa Phage cocktail WRAIR-PAM-CF1 with titer between 4 x 10 7 and 4 x 10 9 PFU given intravenously National Institute of Allergy and Infectious Diseases (NIAID) NCT05453578 SideStream ® , Philips Respironics, Amsterdam, The Netherlands Table 1 Ongoing phage therapy clinical trials for treatment of respiratory infections

